Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Add To Watchlist

Recent & Breaking News (GREY:OBSEF)

ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13-14, 2019

GlobeNewswire August 9, 2019

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

GlobeNewswire August 7, 2019

ObsEva Reports Second Quarter 2019 Financial Results

GlobeNewswire August 7, 2019

ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019

GlobeNewswire August 5, 2019

ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022

GlobeNewswire July 26, 2019

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

GlobeNewswire July 18, 2019

ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban

GlobeNewswire July 17, 2019

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City

GlobeNewswire July 12, 2019

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

GlobeNewswire July 8, 2019

ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs

GlobeNewswire July 1, 2019

ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna

GlobeNewswire June 21, 2019

ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting

GlobeNewswire June 19, 2019

ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes

GlobeNewswire June 4, 2019

ObsEva Reports First Quarter 2019 Financial Results

GlobeNewswire May 9, 2019

ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

GlobeNewswire May 9, 2019

ObsEva SA Announces that ObsEva's Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019

GlobeNewswire May 8, 2019

ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain

GlobeNewswire May 3, 2019

ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019

GlobeNewswire May 1, 2019

ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

GlobeNewswire April 29, 2019

ObsEva SA to Participate in Upcoming Investor Conferences

GlobeNewswire April 1, 2019